JP6050227B2 - 多価糖ペプチド構築物およびその使用 - Google Patents

多価糖ペプチド構築物およびその使用 Download PDF

Info

Publication number
JP6050227B2
JP6050227B2 JP2013514400A JP2013514400A JP6050227B2 JP 6050227 B2 JP6050227 B2 JP 6050227B2 JP 2013514400 A JP2013514400 A JP 2013514400A JP 2013514400 A JP2013514400 A JP 2013514400A JP 6050227 B2 JP6050227 B2 JP 6050227B2
Authority
JP
Japan
Prior art keywords
composition
item
cancer
carbohydrate
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013514400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528229A5 (https=
JP2013528229A (ja
Inventor
サミュエル ジェイ． ダニシェフスキー，
サミュエル ジェイ． ダニシェフスキー，
ゴビンド ラグパティ，
ゴビンド ラグパティ，
フィリップ オー． リビングストン，
フィリップ オー． リビングストン，
ジャンロン ジュ，
ジャンロン ジュ，
カーシック イアー，
カーシック イアー，
グワンビン ヤン，
グワンビン ヤン，
Original Assignee
スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ
スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ, スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ filed Critical スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ
Publication of JP2013528229A publication Critical patent/JP2013528229A/ja
Publication of JP2013528229A5 publication Critical patent/JP2013528229A5/ja
Application granted granted Critical
Publication of JP6050227B2 publication Critical patent/JP6050227B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2013514400A 2010-06-11 2011-06-10 多価糖ペプチド構築物およびその使用 Expired - Fee Related JP6050227B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35372210P 2010-06-11 2010-06-11
US61/353,722 2010-06-11
PCT/US2011/040074 WO2011156774A2 (en) 2010-06-11 2011-06-10 Multivalent glycopeptide constructs and uses thereof

Publications (3)

Publication Number Publication Date
JP2013528229A JP2013528229A (ja) 2013-07-08
JP2013528229A5 JP2013528229A5 (https=) 2014-07-24
JP6050227B2 true JP6050227B2 (ja) 2016-12-21

Family

ID=45098716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013514400A Expired - Fee Related JP6050227B2 (ja) 2010-06-11 2011-06-10 多価糖ペプチド構築物およびその使用

Country Status (8)

Country Link
US (1) US9493580B2 (https=)
EP (1) EP2579893A4 (https=)
JP (1) JP6050227B2 (https=)
CN (1) CN103108654A (https=)
AU (1) AU2011265184B2 (https=)
CA (1) CA2801922A1 (https=)
NZ (1) NZ604089A (https=)
WO (1) WO2011156774A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5111705B2 (ja) 1999-08-20 2013-01-09 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ 新規な複合多糖、グリコアミノ酸、これらへの中間体、及びこれらの使用
WO2010006343A2 (en) 2008-07-11 2010-01-14 Sloan-Kettering Institute For Cancer Research Glycopeptide constructs and uses thereof
US8900635B2 (en) 2010-11-15 2014-12-02 Humanetics Corporation Nanoparticle isoflavone compositions and methods of making and using the same
TR201808684T4 (tr) * 2012-10-02 2018-07-23 Glaxosmithkline Biologicals Sa Lineer olmayan sakarit konjügatları.
CN111499679B (zh) * 2013-01-04 2021-07-06 台湾浩鼎生技股份有限公司 具有较高碳水化合物抗原密度的疫苗及新颖皂素佐剂
BR112015032713B1 (pt) * 2013-09-17 2023-03-21 Obi Pharma, Inc Composto, composição farmacêutica, uso de uma quantidade terapeuticamente efetiva da composição farmacêutica, e uso do composto
US10738134B2 (en) 2013-09-27 2020-08-11 Virginia Tech Intellectual Properties, Inc. Cross-metathesized polysaccharide derivatives and processes for preparing them
US9084726B2 (en) * 2013-11-26 2015-07-21 Humanetics Corporation Suspension compositions of physiologically active phenolic compounds and methods of making and using the same
US9994605B2 (en) 2014-03-13 2018-06-12 Universitaet Basel Carbohydrate ligands that bind to IgM antibodies against myelin-associated glycoprotein
US10851179B2 (en) 2014-03-14 2020-12-01 Virginia Tech Intellectual Properties, Inc. Polysaccharide derivatives and cross-metathesis processes for preparing them
JP2017518958A (ja) 2014-03-19 2017-07-13 マッカイ メディカル ファウンデイション ザ プレスビテリアン チャーチ イン タイワン マッカイ メモリアル ホスピタルＭａｃｋａｙ Ｍｅｄｉｃａｌ Ｆｏｕｎｄａｔｉｏｎ Ｔｈｅ Ｐｒｅｓｂｙｔｅｒｉａｎ Ｃｈｕｒｃｈ Ｉｎ Ｔａｉｗａｎ Ｍａｃｋａｙ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用
JP6590474B2 (ja) * 2014-09-25 2019-10-16 国立大学法人埼玉大学 化学架橋ペプチドの作製方法、その方法を用いて作製した化学架橋ペプチド及びそのペプチドを用いて構築したｃＤＮＡディスプレイ法によるペプチドライブラリ
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
CA2996073A1 (en) * 2015-09-16 2017-03-23 Universitat Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
BR112018070097A2 (pt) 2016-03-29 2019-02-12 Obi Pharma, Inc. anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
KR20230110820A (ko) 2016-04-22 2023-07-25 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
CN110072545A (zh) 2016-07-27 2019-07-30 台湾浩鼎生技股份有限公司 免疫原性/治疗性聚糖组合物及其用途
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
TWI822055B (zh) 2016-11-21 2023-11-11 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5576894A (en) 1978-12-05 1980-06-10 Towa Kasei Kogyo Kk Epimerization of aldose
NZ226811A (en) 1987-11-03 1991-06-25 Syntex Inc Adjuvant emulsion comprising a glycopeptide and non-toxic tetra-polyol or pop-poe block copolymer wherein oily particle size is less than 800am
US5708163A (en) 1994-03-15 1998-01-13 Sloan-Kettering Institute Of Cancer Research Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof
US6303120B1 (en) 1994-03-15 2001-10-16 Memorial Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the lewis y epitope and uses thereof
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
AU747899B2 (en) 1997-01-13 2002-05-30 Sloan-Kettering Institute For Cancer Research Colon cancer KH-1 and N3 antigens
WO1998046246A1 (en) 1997-04-16 1998-10-22 Sloan-Kettering Institute For Cancer Research α-O-LINKED GLYCOCONJUGATES WITH CLUSTERED (2,6)-ST EPITOPES, METHODS OF PREPARATION AND USES THEREOF
US7550146B2 (en) 1997-04-16 2009-06-23 Sloan-Kettering Institute For Cancer Research Glycopeptide conjugates and uses thereof
DE69828507T2 (de) 1997-05-20 2006-01-05 Galenica Pharmaceuticals, Inc. Triterpene-saponin analoga mit adjuvans und immunostimulierender wirkung
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
JPH1135594A (ja) 1997-07-24 1999-02-09 Meiji Milk Prod Co Ltd ムチン型糖鎖合成中間体
EP1017419A4 (en) 1997-09-25 2004-12-29 Sloan Kettering Institutefor C FUCOSYL-GM1-KLH CONJUGATE VACCINE AGAINST SMALL CELL LUNG CANCER
DE19802748A1 (de) 1998-01-26 1999-07-29 Chemtec Leuna Ges Fuer Chemie Verfahren zur enzymatischen Synthese von Glycoaminosäurederivaten
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
JP2002507577A (ja) 1998-03-25 2002-03-12 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ 三量体抗原性ｏ−結合複合糖ペプチド、その製造方法及びその使用
EP1080370A4 (en) 1998-05-29 2003-07-30 Epimmune Inc IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
JP5111705B2 (ja) 1999-08-20 2013-01-09 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ 新規な複合多糖、グリコアミノ酸、これらへの中間体、及びこれらの使用
US7854934B2 (en) * 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
JP2004534088A (ja) 2001-07-06 2004-11-11 スローン−ケッタリング・インスティテュート・フォア・キャンサー・リサーチ 癌のための多価コンジュゲートワクチン
WO2004060915A2 (en) 2002-12-03 2004-07-22 Sloan-Kettering Institute For Cancer Research Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
WO2004050711A2 (en) 2002-12-03 2004-06-17 Sloan-Kettering Institute For Cancer Research Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
US7635750B2 (en) 2003-09-05 2009-12-22 Sloan-Kettering Institute For Cancer Research Method for preparing polyfunctionalized peptides and/or proteins via native chemical ligation
WO2007146070A2 (en) 2006-06-08 2007-12-21 University Of Georgia Research Foundation, Inc. Liposome-mediated native chemical ligation
WO2007079448A2 (en) 2006-01-03 2007-07-12 University Of Georgia Research Foundation, Inc. Three component carbohydrate vaccine
AU2009268937A1 (en) 2008-06-16 2010-01-14 Aj Park Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment
WO2010006343A2 (en) * 2008-07-11 2010-01-14 Sloan-Kettering Institute For Cancer Research Glycopeptide constructs and uses thereof

Also Published As

Publication number Publication date
US20130095173A1 (en) 2013-04-18
AU2011265184A1 (en) 2013-01-10
EP2579893A4 (en) 2014-01-01
EP2579893A2 (en) 2013-04-17
WO2011156774A3 (en) 2012-04-19
NZ604089A (en) 2015-03-27
CA2801922A1 (en) 2011-12-15
JP2013528229A (ja) 2013-07-08
US9493580B2 (en) 2016-11-15
CN103108654A (zh) 2013-05-15
WO2011156774A2 (en) 2011-12-15
AU2011265184B2 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
JP6050227B2 (ja) 多価糖ペプチド構築物およびその使用
KR102453184B1 (ko) 트리테르펜 사포닌, 그의 합성 방법, 및 그의 용도
US20240327443A1 (en) Triterpene saponin analogues
US9598466B2 (en) Glycopeptide constructs and uses thereof
KR102424785B1 (ko) 최소 사포닌 유사체, 이의 합성법 및 용도
JP7177082B2 (ja) トリテルペンサポニン類似物
JP2021152043A5 (https=)
JP2022191284A (ja) トリテルペンサポニン類似物
AU2014271331A1 (en) Glycopeptide constructs and uses thereof
US20250092085A1 (en) Saponin-based adjuvants and vaccines
EP4466278A1 (en) Saponin-based adjuvants and vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140609

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140609

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20151130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160902

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161124

R150 Certificate of patent or registration of utility model

Ref document number: 6050227

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees